Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.

ABSTRACT:

Abstract

An increased risk of second primary malignancies (SPMs) was reported for transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) exposed to lenalidomide (Len), with the caveats that Len was often coexposed to alkylating agents and the studies did not exclude synchronous malignancies (SyMs). We aimed to evaluate the respective SyM over SPM risks in TI patients with NDMM treated with Len as frontline therapy. We conducted a high-resolution, population-based cancer registry study, which allowed completeness of the primary end point (SyMs and SPMs) without reporting bias, and provided a cohort more representative of real-life than those in clinical trials. The inclusion period started recently (2018) due to the reimbursement of Len in France. Additiona

SUBMITTER: Systchenko T 

PROVIDER: S-EPMC12686782 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature